This study outcome suggests that combinational therapy utilizing NKG2D-based CAR T cells and lenalidomide has a high potential for effectively eliminating tumor cells in vitro and that immunomodulatory medication lenalidomide (LEN) may increase the effectiveness of CAR T cells in the treatment of solid tumors. Here, KLRK1 is linked to neoplasm.